EPILOG Results: Balloon Angioplasty/Bail-out Stenting

Slides:

Advertisements

Similar presentations

Stone p2203/Abstract/ Conclusions

Advertisements

Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade Findings of the ESPRIT Trial James E.

Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,

Intravenous GP IIb/IIIa Inhibitors Abciximab (c7E3 Fab, ReoPro) = Human- murine chimeric monoclonal Fab antibody fragment Eptifibatide (Integrilin) =

Clinical Trials of GP IIb/IIIa Inhibition Major Trials of GP IIb/IIIa Inhibitors in ACS GP IIb/IIIa Inhibitors in PCI GP IIb/IIIa Inhibition in Patients.

RE-MEDY Cumulative Risk Recurrent Venous Thromboembolism or Related Death in the Active-Control Study Months since Randomization Estimated Cumulative Risk.

Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.

What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.

STEMI < 6 h Lytic eligible Lytic choice by MD (TNK, tPA, rPA, SK) ENOX < 75 y: 30 mg IV bolus SC 1.0 mg / kg q 12 h (Hosp DC) ≥ 75 y: No bolus SC 0.75.

Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.

ReoPro ® in NSTEMI and STEMI Trials Harald Vangerow, MD Clinical Research Physician Eli Lilly UK.

Www. Clinical trial results.org Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50.

High-Dose, Double-Bolus Eptifibatide (Integrilin™) in Non- Urgent Coronary Stent Intervention 6 Month Results of the ESPRIT Trial.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Relative Risk Therapy A Better Therapy B Better COMPASS 95% CI no worse than 1.5 TARGET 95% CI no worse than 1.47 ASSENT-2.

ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.

The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.

NSTE Acute Coronary Syndromes

VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

NICE-3 National Investigators Collaborating on Enoxaparin XXII nd Congress of the European Society of Cardiology August 30, 2000 Amsterdam, The Netherlands.

TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,

CAPTURE: C 7E3 Fab A nti- P latelet T herapy in U nstable RE fractory Angina ¤ Study Population:Patients with chest pain at rest and ECG signs of UA (NQMI.

AHA 2011 Late Breaking Trials Synthesis and Critical Review.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.

1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:

(p for noninferiority = 0.01)

Tirofiban Meta-Analysis

The American College of Cardiology Presented by Dr. Adnan Kastrati

Figure 1 Ischaemic endpoints

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

TAXUS II: Slow Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUSTM NIRxTM SR Stent Presented at TCT 2002.

For the HORIZONS-AMI Investigators

FINESSE: Study Design Acute ST Elevation MI (or New LBBB) within 6h pain onset Presenting at Hub or Spoke with estimated time to Cath between 1 and 4 hours.

HOPE: Heart Outcomes Prevention Evaluation study

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

Study Design AMI <12 hours, any age, cardiogenic shock excluded

Valsartan in Acute Myocardial Infarction Trial Investigators

Preventing Thrombotic Complications in ACS: State of the Art

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

What Has Been Tried and What Is True?

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Late Breaking Clinical Trials

European Society of Cardiology 2003

TAXUS II: Moderate Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUSTM NIRxTM MR Stent Presented at TCT 2002.

The HORIZONS-AMI Trial

BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.

EPIC: Balloon Angioplasty

Probability of No Urgent Repeated Percutaneous Revascularization Procedures in the Three Treatment Groups (Kaplan-Meier Plots) Figure 1. Probability of.

For the HORIZONS-AMI Investigators

For the HORIZONS-AMI Investigators

Published in the European Heart Journal

ARNO TRIAL (Antithrombotic Regimens aNd Outcome)

Randomized Comparison in the Setting of Acute MI

The ESPRIT Trial 6 Month and 1 Year Results

American Heart Association Presented by Dr. Julinda Mehilli

American College of Cardiology Presented by Dr. Michel R. Le May

(p = 0.32 for noninferiority)

Drug-eluting stents for in-stent restenosis

Role of Stenting in Acute MI: PAMI Stent Pilot Trial

Elevated Admission Plasma Glucose Following ACS

Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation

IMPACT II Results: Balloon Angioplasty/Bail-out Stenting

MACE: Death, MI or TLR at 5 years

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Primary safety endpoint

FIELD: Primary outcome

Presentation transcript:

EPILOG Results: Balloon Angioplasty/Bail-out Stenting Primary Endpoint Result: Death, MI, UTVR at 30 days 6.5%  (P<0.001) Placebo + heparin (ACT  300 sec) (n=939) Abciximab + heparin (ACT  300 sec) (n=918) Abciximab + heparin (ACT  200 sec) (n=935) 6.3%  (P<0.001) % events 11.7% 5.4% 5.2% The EPILOG investigators. N. Engl J Med. 1997; 336: 1689-1696.

EPILOG Results 30 Day Death/MI 5.3%  (P<0.0001) 6 Month Death/MI 5.3%  (P<0.001) 30 Day TVR 1.8%  (P<0.05) 6 Month TVR 1.1% (P=ns) Placebo + heparin (ACT  300 sec) (n=939) Abciximab + heparin (ACT  200 sec) (n=935) 18.1% % events 17.0% 11.1% Major TIMI Bleeding 9.1% 5.8% 3.8% 3.6% 3.1% 1.8% 2.0% The EPILOG investigators. N. Engl J Med. 1997; 336: 1689-1696.